NCT02636127View on ClinicalTrials.gov

Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 7, 2015

Primary Completion Date

July 21, 2016

Study Completion Date

July 8, 2018

Conditions
Scleroderma, Systemic
Interventions
OTHER

blood samples

"one blood sample will be done for dosage and role of Fractalkine in the serum.~\- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release."

Trial Locations (1)

13354

Assistance Publique Hopitaux de Marseille, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER

NCT02636127 - Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis | Biotech Hunter | Biotech Hunter